BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 9016587)

  • 1. Optimal Tat-mediated activation of the HIV-1 LTR promoter requires a full-length TAR RNA hairpin.
    Verhoef K; Tijms M; Berkhout B
    Nucleic Acids Res; 1997 Feb; 25(3):496-502. PubMed ID: 9016587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct transcriptional pathways of TAR-dependent and TAR-independent human immunodeficiency virus type-1 transactivation by Tat.
    Yang L; Morris GF; Lockyer JM; Lu M; Wang Z; Morris CB
    Virology; 1997 Aug; 235(1):48-64. PubMed ID: 9300036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Tat-mediated transactivation of HIV-1 LTR transcription by polyamide nucleic acid targeted to TAR hairpin element.
    Mayhood T; Kaushik N; Pandey PK; Kashanchi F; Deng L; Pandey VN
    Biochemistry; 2000 Sep; 39(38):11532-9. PubMed ID: 10995220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tat functions to stimulate the elongation properties of transcription complexes paused by the duplicated TAR RNA element of human immunodeficiency virus 2.
    García-Martínez LF; Mavankal G; Peters P; Wu-Baer F; Gaynor RB
    J Mol Biol; 1995 Dec; 254(3):350-63. PubMed ID: 7490754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exon2 of HIV-2 Tat contributes to transactivation of the HIV-2 LTR by increasing binding affinity to HIV-2 TAR RNA.
    Rhim H; Rice AP
    Nucleic Acids Res; 1994 Oct; 22(21):4405-13. PubMed ID: 7971271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Jembrana disease virus Tat can regulate human immunodeficiency virus (HIV) long terminal repeat-directed gene expression and can substitute for HIV Tat in viral replication.
    Chen H; He J; Fong S; Wilcox G; Wood C
    J Virol; 2000 Mar; 74(6):2703-13. PubMed ID: 10684286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of YB-1 with human immunodeficiency virus type 1 Tat and TAR RNA modulates viral promoter activity.
    Ansari SA; Safak M; Gallia GL; Sawaya BE; Amini S; Khalili K
    J Gen Virol; 1999 Oct; 80 ( Pt 10)():2629-2638. PubMed ID: 10573156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the tat and nef gene products of human immunodeficiency virus type 1 (HIV-1) on transcription controlled by the HIV-1 long terminal repeat and on cell growth in macrophages.
    Murphy KM; Sweet MJ; Ross IL; Hume DA
    J Virol; 1993 Dec; 67(12):6956-64. PubMed ID: 8230418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr virus nuclear antigen 2 transactivates the long terminal repeat of human immunodeficiency virus type 1.
    Scala G; Quinto I; Ruocco MR; Mallardo M; Ambrosino C; Squitieri B; Tassone P; Venuta S
    J Virol; 1993 May; 67(5):2853-61. PubMed ID: 8386279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transdominant mutants of I kappa B alpha block Tat-tumor necrosis factor synergistic activation of human immunodeficiency virus type 1 gene expression and virus multiplication.
    Beauparlant P; Kwon H; Clarke M; Lin R; Sonenberg N; Wainberg M; Hiscott J
    J Virol; 1996 Sep; 70(9):5777-85. PubMed ID: 8709193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. tat regulates binding of the human immunodeficiency virus trans-activating region RNA loop-binding protein TRP-185.
    Wu F; Garcia J; Sigman D; Gaynor R
    Genes Dev; 1991 Nov; 5(11):2128-40. PubMed ID: 1936997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recruitment of cyclin T1/P-TEFb to an HIV type 1 long terminal repeat promoter proximal RNA target is both necessary and sufficient for full activation of transcription.
    Bieniasz PD; Grdina TA; Bogerd HP; Cullen BR
    Proc Natl Acad Sci U S A; 1999 Jul; 96(14):7791-6. PubMed ID: 10393900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Examination of TAR-independent Trans activation by human immunodeficiency virus type 1 Tat in human glial cells.
    Kim YS; Panganiban AT
    J Neurosci Res; 1996 Mar; 43(6):652-66. PubMed ID: 8984195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of HIV-1 Tat-dependent trans activation by steric block chimeric 2'-O-methyl/LNA oligoribonucleotides.
    Arzumanov A; Walsh AP; Rajwanshi VK; Kumar R; Wengel J; Gait MJ
    Biochemistry; 2001 Dec; 40(48):14645-54. PubMed ID: 11724578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tat-regulated production of multimerized TAR RNA inhibits HIV-1 gene expression.
    Lisziewicz J; Rappaport J; Dhar R
    New Biol; 1991 Jan; 3(1):82-9. PubMed ID: 2039768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 Tat protein can transactivate a heterologous TATAA element independent of viral promoter sequences and the trans-activation response element.
    Roebuck KA; Rabbi MF; Kagnoff MF
    AIDS; 1997 Feb; 11(2):139-46. PubMed ID: 9030359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transactivation of heterologous promoters by HIV-1 tat.
    Han P; Brown R; Barsoum J
    Nucleic Acids Res; 1991 Dec; 19(25):7225-9. PubMed ID: 1662814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 regulatory protein tat induces RNA binding proteins in central nervous system cells that associate with the viral trans-acting-response regulatory motif.
    Kundu M; Ansari SA; Chepenik LG; Pomerantz RJ; Khalili K; Rappaport J; Amini S
    J Hum Virol; 1999; 2(2):72-80. PubMed ID: 10225209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tricyclo-DNA containing oligonucleotides as steric block inhibitors of human immunodeficiency virus type 1 tat-dependent trans-activation and HIV-1 infectivity.
    Ivanova G; Reigadas S; Ittig D; Arzumanov A; Andreola ML; Leumann C; Toulmé JJ; Gait MJ
    Oligonucleotides; 2007; 17(1):54-65. PubMed ID: 17461763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TAR-independent activation of the HIV-1 LTR: evidence that tat requires specific regions of the promoter.
    Berkhout B; Gatignol A; Rabson AB; Jeang KT
    Cell; 1990 Aug; 62(4):757-67. PubMed ID: 2201451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.